Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate

Journal of Cardiovascular Pharmacology

Volumn 34, Issue SUPPL. 2, 1999, Pages

  Waller, Derek G ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Angina; Circadian rhythm; Nitrates; Tolerance

Indexed keywords

ISOSORBIDE 5 NITRATE; NITRATE;

ANGINA PECTORIS; CIRCADIAN RHYTHM; CONFERENCE PAPER; CORONARY ARTERY SPASM; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERANCE; EXERCISE TOLERANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; REBOUND; SUSTAINED RELEASE FORMULATION; WAKEFULNESS;

ANGINA PECTORIS; CIRCADIAN RHYTHM; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DRUG TOLERANCE; HUMANS; ISOSORBIDE DINITRATE; NITRATES; VASODILATOR AGENTS;

EID: 0032887045     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908002-00005     Document Type: Conference Paper

References (43)

1. Abrams J. Mechanism of action of the organic nitrates in the treatment of myocardial ischaemia. Am J Cardiol 1992;70:30B-40B.
2. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy of continuous twenty-fourhour application of transdermal nitroglycerin. Am J Cardiol 1987; 60:271-5.
3. Abrams J, Elkayam U, Thadanii U, Fung H-L. Tolerance: An historical overview. Am J Cardiol 1998;81:3A-14A.
4. Bauer JA, Fung H-L. Arterial versus venous metabolism of nitroglycerin to nitric oxide: a possible explanation of organic nitrate veroselectivity. J Cardiovasc Pharmacol 1996;28:371-4.
5. Stewart DJ, Münzel T, Holtz J, Bassenge E. Discrepancy between initial and steady-state resistance vessel responsiveness to shortterm nitroglycerin exposure in the hindlimb of conscious dogs. J Cardiovasc Pharmacol 1988;12:144-51.
6. Selke FW, Myers PR, Bates JW, Harrison DG. Influence of vessel size on the sensitivity of porcine microvessels to nitroglycerin. Am J Physiol 1990;258:H515-520.
7. Ghio S, de Servi S, Perotti R, Eleuteri E, Montemartinic Specchia G. Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans. Circulation 1992;86:798-802.
8. Stewart DJ, Elsner D, Sommer O, Bassenge E. Altered spectrum of nitroglycerin action in long-term treatment: nitroglycerin-specific venous tolerance with maintenance of arterial vasodepressor ptency. Circulation 1986;74:573-82.
9. Parker JO. Intermittent transdermal nitrate therapy in the treatment of chronic stable angina. J Am Cardiol 1989;13:794-5.
10. De Mots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-95.
11. Freedman SB, Daxini BV, Noyce D, Kelly DT. Intermittent transdermal nitrates do not improve ischaemia in patients taking betablockers or calcium antagonists: Potential role of rebound ischaemia during the nitrate-free period. J Am Coll Cardiol 1995; 25:249-55.
12. Pepine CJ, Lopez LM, Bell DM, Handburg-Thurmond EM, Marks RG, McGorray S. Effects of intermittent transdermal nitroglycerin on occurrence of ischaemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-11). J Am Coll Cardiol 1997;30:955-61.
13. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule. Eur Heart J 1989;10:998-1002.
14. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitrate therapy: decreased anginal threshold during the nitrate-free interval. Circulation 1995;91:973-8.
15. Münzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;93:2052-8.
16. Thadani U, Prasal R, Hamilton SF, et al. Usefulness of twice daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol 1987;60:477-82.
17. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina during twice daily therapy with isosorbide mononitrate. Ann Intern Med 1994;120:353-9.
18. Rutherford JD. Nitrate tolerance in angina therapy. How to avoid it. Drugs 1995;49:196-9.
19. Bonn R. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris. Am J Cardiol 1998;61:12E-14E
20. Beyerle A, Reinger G, Rudolph W. Long-acting marked antiischaemic effect maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained release form. Am J Cardiol 1990;65:1434-7.
21. Kenedi P, Gathmann-Lewik U. Dose-effect relationship amongst three different sustained-release forms of isosorbide-5-mononitrate in patients with coronary artery disease. Cardiology 1987;74 (suppl):29-33.
22. Chrysant SG, Classer SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249-56.
23. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin Pharmacol Ther 1988;44:540-5.
24. Olsson G, Allger J. Prophylactic nitrate therapy in angina pectorisis there an optimal treatment regimen? Br J Clin Pharmacol 1992; 34:19S-23S.
25. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994;22:266-72.
26. Neimeyer M, Kleinjans H, de Ree R, Zwinderman AH, Cleophas TJM, Van der Wall E, on behalf of the Dutch mononitrate quality of life study group. Comparison of multi-dose and once-daily nitrate therapy in patients with stable angina pectoris: effects on quality-of-life indices. Curr Ther Res 1996;57:927-36.
27. Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischaemia in patients with coronary artery disease. Circulation 1987;75:395-400.
28. Mulcahy D, Cunningham D, Crean P. Circadian variation of total ischaemic burden and its alteration by antianainal agents. Lancet 1988;ii:755-9.
29. Willich SN, Linderer T, Wegscheider K, et al. Increased morning incidence of myocardial infarctions in the ISAM study: absence with prior beta-adrenergic blockade. Circulation 1989;80:53-8.
30. Parker JD, Testa MA, Jimeney AH, et al. Morning increase in ambulatory ischaemia in patients with stable coronary artery disease: importance of physical activity and increased cardiac demand. Circulation 1994;84:604-14.
31. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet 1978;i:797-9.
32. Northcote RJ, Canning GP, Ballantyne D. Electrocardiographic findings in male veteran endurance athletes. Br Heart J 1989;61:155-60.
33. Furlan R, Guzzetti S, Crivellaro W, et al. Continuous 24 hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation 1990;81:537-47.
34. Panza JA, Epstein SE, Quuyumi AA. Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med 1991;325:989-90.
35. Brugger P. New findings about the night urinary excretion of catecholamines in coronary patients, Wien Med Wochtenschr 1990;14: 375-82.
36. Huikuri HV, Nieneta MJ, Ojala S, et al. Circadian rhythms of frequency domain measures of heart rate variability in healthy subjects and patients with coronary artery disease. Circulation 1994;90:121-6.
37. Marchant B, Stevenson R, Vaishnov S, et al. Influence of the autonomie nervous system on circadian patterns of myocardial ischaemia: expansion of stable angina with the early post-infarction period. Br Heart J 1994;71:329-33.
38. Quuyumi AA, Banza JA, Diodali JG, et al. Circadian variation in ischaemic threshold. A mechanism underlying the circadian variation in ischaemic events. Circulation 1992;86:22-8.
39. Ingendaay A, Klein G, Rehm D, et al. A comparison of the pharmacokinetics of different sustained-release mononitrate presentations. Münch Med Wochenschr 1987;3:34-6.
40. Baxter T, Edie CJ. Twenty-four hour plasma profile of sustained release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials. Br J Clin Pharmacol 1997;43:333-5.
41. Trenk D, Hinder M, Bonn R, Stengele E, Jänchen E. Onset of haemodynamic effects of isosorbide-5-mononitrate is not delayed following administration of a sustained-release preparation [abstract]. Eur J Clin Pharm 1997;52.
42. Guzik J, Kanopka M, Maciejewicz J, Maziarz A, Stepien J. Sustained-release isosorbide-5-mononitrate improves exercise capacity 30 minutes after oral application. Clin Drug Invest 1997; 14:117-24.
43. Nessler B, Plowowarska J, Nessler J, Stepien J. Comparison of the onset of 2 different isosorbide-5-mononitrate formulations in patients with coronary artery disease and stable exercise-induced angina pcctoris. Bulg Kardiologika 1996;96:A10.